Positrigo, a Swiss-based innovator in the field of nuclear medical imaging, has reached a significant milestone by securing the CE Mark in Europe for its dedicated brain Positron Emission Tomography (PET) system, NeuroLF®. This state-of-the-art imaging technology is ultra-compact and is designed to aid in the diagnosis and monitoring of various brain disorders, including Alzheimer’s disease, brain tumours, epilepsy, and Parkinson’s disease, among others.
A Milestone in Medical Imaging
Prof. Dr. med. Osama Sabri, Director and Chairman of the Department of Nuclear Medicine at the University of Leipzig Medical Centre, commented, “The CE Mark for the NeuroLF system marks an important achievement in the evolution of brain PET imaging. This technology significantly enhances the availability of dedicated brain PET imaging, empowering nuclear medicine physicians across Europe to utilise a specialised tool for diagnosing and monitoring brain-related conditions.”
The NeuroLF system boasts a compact design that is not only more affordable but also lighter than conventional clinical hybrid PET systems, which typically have larger footprints and are integrated with either MRI or CT. Dr. Jannis Fischer, co-founder and CEO of Positrigo, stated, “At Positrigo, our mission is to expand the frontiers of medical imaging by developing and commercialising innovative technologies. The CE Mark for the NeuroLF system validates our efforts, providing healthcare professionals with a powerful tool to enhance the diagnosis and management of brain disorders like Alzheimer’s disease while establishing a new benchmark in brain PET imaging.”
Addressing the Growing Demand for Brain PET Imaging
The European Association of Nuclear Medicine (EANM) Neuroimaging Committee has indicated that amyloid PET imaging is at a critical juncture, with the potential to significantly improve early diagnosis of Alzheimer’s disease. Experts anticipate that the application of amyloid PET will increase substantially in the near future, particularly in justifying the initiation and monitoring of disease-modifying therapies based on biological evidence. Estimates suggest that the demand for amyloid PET could surge by as much as 20 times.
With the NeuroLF system receiving clearance in the European market, Positrigo is strategically positioned to improve the PET imaging infrastructure required to address this increasing demand.
Strategic Commercialisation Plans in Europe
Positrigo aims to commercialise its groundbreaking technology across Europe by collaborating with established companies in select countries. Dr. Stefan Bircher, Chief Commercial Officer at Positrigo, explained, “Given the fragmented nature of the healthcare system in Europe, which involves various country-specific purchasing mechanisms and reimbursement models, partnering with local firms allows us to optimise our commercial strategy. This approach will help us gain rapid traction in the market while ensuring we can deliver top-notch after-sales support.”
The NeuroLF system is the first dedicated brain imaging device to receive market clearance in both Europe and the United States. These approvals represent pivotal steps towards unlocking commercial opportunities in other regions worldwide.
Conclusion
With the introduction of the NeuroLF system, Positrigo is set to revolutionise the landscape of brain imaging. By providing advanced diagnostic tools that meet the growing needs of healthcare professionals, Positrigo aims to improve patient outcomes and advance the field of nuclear medicine.